{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-002577","form_type":"8-K","ticker":"DMRA","cik":"0001800315","company_name":"Damora Therapeutics, Inc.","filed_at":"2022-01-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.272072+00:00","generated_at":"2026-06-27T15:03:07.980248+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Galecto reports safety and efficacy of GB0139 in COVID-19; 21% mortality reduction in high-risk subgroup","bullets":["Study met primary safety endpoint: no treatment-related adverse events in 20 GB0139 patients.","Target engagement confirmed: statistically significant reduction in serum galectin-3 (p<0.01).","GB0139-treated patients had significantly greater rate of decline in oxygen requirement vs standard of care.","In high-risk subgroup, 21% mortality reduction observed; company plans co-development for COVID-19.","GALACTIC-1 IPF trial: amendment to reduce target patients, topline expected mid-2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-002577","json":"https://secwatch.observer/filing/0001564590-22-002577.json","markdown":"https://secwatch.observer/filing/0001564590-22-002577.md","text":"https://secwatch.observer/filing/0001564590-22-002577.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800315/000156459022002577/0001564590-22-002577-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800315/000156459022002577/glto-8k_20220127.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T15:03:07.980248+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}